Eagle Pharmaceuticals, Inc.
EGRX · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $15 | $22 | $55 | $15 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $116 | $116 | $73 | $98 |
| Inventory | $42 | $44 | $48 | $64 |
| Other Curr. Assets | $13 | $19 | $22 | $15 |
| Total Curr. Assets | $187 | $192 | $189 | $185 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $45 | $45 | $45 | $42 |
| Intangibles | $107 | $113 | $118 | $109 |
| Long-Term Investments | $18 | $18 | $10 | $11 |
| Tax Assets | $31 | $29 | $27 | $24 |
| Other NC Assets | $15 | $15 | $16 | $18 |
| Total NC Assets | $218 | $222 | $217 | $205 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $405 | $414 | $406 | $390 |
| Liabilities | – | – | – | – |
| Payables | $16 | $17 | $19 | $13 |
| Short-Term Debt | $10 | $9 | $8 | $36 |
| Tax Payable | $1 | $13 | $5 | $6 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $60 | $59 | $79 | $66 |
| Total Curr. Liab. | $87 | $98 | $111 | $122 |
| LT Debt | $62 | $69 | $60 | $28 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $5 |
| Other NC Liab. | $4 | $5 | $2 | $0 |
| Total NC Liab. | $66 | $74 | $62 | $33 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $2 | $5 | $3 |
| Total Liabilities | $153 | $171 | $173 | $155 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | $122 | $117 | $112 | $107 |
| AOCI | -$1 | -$1 | -$1 | $9 |
| Other Equity | $131 | $127 | $123 | $119 |
| Total Equity | $252 | $243 | $234 | $235 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $405 | $414 | $406 | $390 |
| Net Debt | $56 | $56 | $12 | $49 |